Literature DB >> 19797124

Foxl2, a forkhead transcription factor, modulates nonclassical activity of the estrogen receptor-alpha.

So-Youn Kim1, Jeffrey Weiss, Minghan Tong, Monica M Laronda, Eun-Jig Lee, J Larry Jameson.   

Abstract

Foxl2 is a forkhead transcription factor required for ovary development and ovarian follicle maturation. In this report, we identified and characterized a functional relationship between Foxl2 expression and estrogen receptor (ER)-alpha signaling. We show that Foxl2 has no effect on classical ERalpha-mediated transcription, which occurs through canonical estrogen response elements. However, Foxl2 suppresses ERalpha signaling through nonclassical tethered transcriptional pathways. Specifically, the selective ER modulator tamoxifen stimulates activator protein-1 (AP1)-dependent transcription via the ERalpha, and this enhancement is blocked by Foxl2. Two lines of evidence suggest that Foxl2 suppression is mediated by physical interactions with ERalpha rather than direct action at AP1 binding sites. First, ERalpha is coimmunoprecipitated with Foxl2. Second, activation of a upstream activating sequence (UAS) reporter by Gal4-cJun in the presence of ERalpha and tamoxifen was blocked by Foxl2, demonstrating suppression in the absence of an AP1 site. Cyclooxygenase-2 (COX2), which is required for ovulation, was identified through expression profiling as a candidate physiological target for nonclassical ERalpha signaling and thus modulation by ERalpha/Foxl2 interactions. This possibility was confirmed by two sets of experiments. COX2 protein levels were induced by ERalpha in the presence of tamoxifen, and protein expression was suppressed by Foxl2. In addition, ERalpha stimulation of the COX2 promoter was repressed by Foxl2. We conclude that ERalpha and Foxl2 interact and that Foxl2 selectively suppresses ERalpha-mediated transcription of AP1-regulated genes. These data provide a potential point of convergence for ERalpha and Foxl2 to regulate ovarian development and function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19797124      PMCID: PMC2775987          DOI: 10.1210/en.2009-0313

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  39 in total

Review 1.  Tamoxifen, raloxifene, and the prevention of breast cancer.

Authors:  V C Jordan; M Morrow
Journal:  Endocr Rev       Date:  1999-06       Impact factor: 19.871

2.  Multiple female reproductive failures in cyclooxygenase 2-deficient mice.

Authors:  H Lim; B C Paria; S K Das; J E Dinchuk; R Langenbach; J M Trzaskos; S K Dey
Journal:  Cell       Date:  1997-10-17       Impact factor: 41.582

3.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Mutation of FOXL2 in granulosa-cell tumors of the ovary.

Authors:  Sohrab P Shah; Martin Köbel; Janine Senz; Ryan D Morin; Blaise A Clarke; Kimberly C Wiegand; Gillian Leung; Abdalnasser Zayed; Erika Mehl; Steve E Kalloger; Mark Sun; Ryan Giuliany; Erika Yorida; Steven Jones; Richard Varhol; Kenneth D Swenerton; Dianne Miller; Philip B Clement; Colleen Crane; Jason Madore; Diane Provencher; Peter Leung; Anna DeFazio; Jaswinder Khattra; Gulisa Turashvili; Yongjun Zhao; Thomas Zeng; J N Mark Glover; Barbara Vanderhyden; Chengquan Zhao; Christine A Parkinson; Mercedes Jimenez-Linan; David D L Bowtell; Anne-Marie Mes-Masson; James D Brenton; Samuel A Aparicio; Niki Boyd; Martin Hirst; C Blake Gilks; Marco Marra; David G Huntsman
Journal:  N Engl J Med       Date:  2009-06-10       Impact factor: 91.245

5.  Generation and reproductive phenotypes of mice lacking estrogen receptor beta.

Authors:  J H Krege; J B Hodgin; J F Couse; E Enmark; M Warner; J F Mahler; M Sar; K S Korach; J A Gustafsson; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

6.  Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

Authors:  K Paech; P Webb; G G Kuiper; S Nilsson; J Gustafsson; P J Kushner; T S Scanlan
Journal:  Science       Date:  1997-09-05       Impact factor: 47.728

7.  A high-efficiency HeLa cell nuclear transcription extract.

Authors:  D J Shapiro; P A Sharp; W W Wahli; M J Keller
Journal:  DNA       Date:  1988 Jan-Feb

8.  Cloning of the human oestrogen receptor cDNA.

Authors:  S Green; P Walter; G Greene; A Krust; C Goffin; E Jensen; G Scrace; M Waterfield; P Chambon
Journal:  J Steroid Biochem       Date:  1986-01       Impact factor: 4.292

9.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.

Authors:  M Sato; M K Rippy; H U Bryant
Journal:  FASEB J       Date:  1996-06       Impact factor: 5.191

10.  Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development.

Authors:  Manuela Uda; Chris Ottolenghi; Laura Crisponi; Jose Elias Garcia; Manila Deiana; Wendy Kimber; Antonino Forabosco; Antonio Cao; David Schlessinger; Giuseppe Pilia
Journal:  Hum Mol Genet       Date:  2004-03-31       Impact factor: 6.150

View more
  10 in total

1.  The forkhead transcription factor FOXK2 promotes AP-1-mediated transcriptional regulation.

Authors:  Zongling Ji; Ian J Donaldson; Jingru Liu; Andrew Hayes; Leo A H Zeef; Andrew D Sharrocks
Journal:  Mol Cell Biol       Date:  2011-11-14       Impact factor: 4.272

2.  Estrogenic modulation of inflammation-related genes in male rats following volume overload.

Authors:  Jennifer L McLarty; Giselle C Meléndez; Scott P Levick; Shanté Bennett; Tara Sabo-Attwood; Gregory L Brower; Joseph S Janicki
Journal:  Physiol Genomics       Date:  2012-01-24       Impact factor: 3.107

3.  Cooperative effects of 17β-estradiol and oocyte-derived paracrine factors on the transcriptome of mouse cumulus cells.

Authors:  Chihiro Emori; Karen Wigglesworth; Wataru Fujii; Kunihiko Naito; John J Eppig; Koji Sugiura
Journal:  Endocrinology       Date:  2013-09-13       Impact factor: 4.736

Review 4.  Neuroprotective actions of estradiol and novel estrogen analogs in ischemia: translational implications.

Authors:  Anne M Etgen; Teresa Jover-Mengual; R Suzanne Zukin
Journal:  Front Neuroendocrinol       Date:  2010-12-14       Impact factor: 8.606

Review 5.  Minireview: roles of the forkhead transcription factor FOXL2 in granulosa cell biology and pathology.

Authors:  Margareta D Pisarska; Gillian Barlow; Fang-Ting Kuo
Journal:  Endocrinology       Date:  2011-01-19       Impact factor: 4.736

6.  Effects of tamoxifen on autosomal genes regulating ovary maintenance in adult mice.

Authors:  Mingxi Yu; Wei Liu; Jingyun Wang; Junwen Qin; Yongan Wang; Yu Wang
Journal:  Environ Sci Pollut Res Int       Date:  2015-08-26       Impact factor: 4.223

7.  FOXL2C134W-Induced CYP19 Expression via Cooperation With SMAD3 in HGrC1 Cells.

Authors:  Martina Belli; Nahoko Iwata; Tomoko Nakamura; Akira Iwase; Dwayne Stupack; Shunichi Shimasaki
Journal:  Endocrinology       Date:  2018-04-01       Impact factor: 4.736

8.  Novel action of FOXL2 as mediator of Col1a2 gene autoregulation.

Authors:  Mara Marongiu; Manila Deiana; Loredana Marcia; Andrea Sbardellati; Isadora Asunis; Alessandra Meloni; Andrea Angius; Roberto Cusano; Angela Loi; Francesca Crobu; Giorgio Fotia; Francesco Cucca; David Schlessinger; Laura Crisponi
Journal:  Dev Biol       Date:  2016-05-19       Impact factor: 3.582

9.  Aromatase is a direct target of FOXL2: C134W in granulosa cell tumors via a single highly conserved binding site in the ovarian specific promoter.

Authors:  Nicholas I Fleming; Kevin C Knower; Kyren A Lazarus; Peter J Fuller; Evan R Simpson; Colin D Clyne
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

10.  Oleic acid induces down-regulation of the granulosa cell identity marker FOXL2, and up-regulation of the Sertoli cell marker SOX9 in bovine granulosa cells.

Authors:  Vengala Rao Yenuganti; Jens Vanselow
Journal:  Reprod Biol Endocrinol       Date:  2017-07-26       Impact factor: 5.211

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.